PMID- 33034815
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1573-7276 (Electronic)
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 37
IP  - 6
DP  - 2020 Dec
TI  - Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan 
      following right hemihepatectomy in patients with cholangiocarcinoma and 
      metastatic uveal melanoma: peri- and post-interventional adverse events and 
      therapy response compared to a matched group without prior liver surgery.
PG  - 683-692
LID - 10.1007/s10585-020-10057-9 [doi]
AB  - To evaluate feasibility, frequency and severity of peri-procedural complications 
      and post-procedural adverse events (AEs) in patients with advanced 
      cholangiocarcinoma or liver metastasis of uveal melanoma and prior 
      hemihepatectomy undergoing chemosaturation percutaneous hepatic perfusion 
      (CS-PHP) and to analyze therapy response and overall survival compared to a 
      matched group without prior surgery. CS-PHP performed between 10/2014 and 02/2018 
      were retrospectively assessed. To determine peri-procedural safety and 
      post-procedural adverse events, hospital records and hematological, hepatic and 
      biliary function were categorized using Common Terminology Criteria for Adverse 
      Events (CTCAE) v5.0 (1-5; mild-death). Significance was tested using Wilcoxon 
      signed-rank and Mann-Whitney U test. Kaplan-Meier estimation and log-rank test 
      assessed survival. Overall 21 CS-PHP in seven patients (4/7 males; 52 +/- 10 years) 
      with hemihepatectomy (group(hemihep)) and 22 CS-PHP in seven patients (3/7 males; 
      63 +/- 12 years) without prior surgery (group(noresection)) were included. No 
      complications occurred during the CS-PHP procedures. Transient changes (CTCAE 
      grade 1-2) of liver enzymes and blood cells followed all procedures. In 
      comparison, group(hemihep) presented slightly more AEs grade 3-4 (e.g. 
      thrombocytopenia in 57% (12/21) vs. 41% (9/22; p = 0.37)) 5-7 days after CS-PHP. 
      These AEs were self-limiting or responsive to treatment (insignificant difference 
      of pre-interventional to 21-45 days post-interventional values (p > 0.05)). One 
      patient in group(hemihep) with high tumor burden died eight days following 
      CS-PHP. No deaths occurred in group(noresection). In comparison, overall survival 
      after first diagnosis was insignificantly shorter in group(noresection) 
      (44.7(32-56.1) months) than in group(hemihep) (48.3(34.6-72.8) months; p = 0.48). 
      The severity of adverse events following CS-PHP in patients after hemihepatectomy 
      was comparable to a matched group without prior liver surgery. Thus, the 
      performance of CS-PHP is not substantially compromised by a prior 
      hemihepatectomy.
FAU - Dewald, C L A
AU  - Dewald CLA
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Becker, L S
AU  - Becker LS
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Maschke, S K
AU  - Maschke SK
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Meine, T C
AU  - Meine TC
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Alten, T A
AU  - Alten TA
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Kirstein, M M
AU  - Kirstein MM
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical 
      School, Hannover, Germany.
FAU - Vogel, A
AU  - Vogel A
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical 
      School, Hannover, Germany.
FAU - Wacker, F K
AU  - Wacker FK
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Meyer, B C
AU  - Meyer BC
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany.
FAU - Hinrichs, J B
AU  - Hinrichs JB
AUID- ORCID: 0000-0002-0135-7082
AD  - Department of Diagnostic and Interventional Radiology, Institute for Diagnostic 
      and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 
      30625, Hannover, Germany. hinrichs.jan@mh-hannover.de.
LA  - eng
PT  - Journal Article
DEP - 20201009
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - Q41OR9510P (Melphalan)
RN  - Uveal melanoma
SB  - IM
MH  - Antineoplastic Agents, Alkylating/administration & dosage/adverse effects
MH  - Bile Duct Neoplasms/*drug therapy/secondary
MH  - Chemotherapy, Cancer, Regional Perfusion/adverse effects/*methods
MH  - Cholangiocarcinoma/*drug therapy/secondary
MH  - Combined Modality Therapy
MH  - Female
MH  - Hepatectomy/adverse effects/methods
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/secondary/*surgery
MH  - Male
MH  - Melanoma/*drug therapy/pathology
MH  - Melphalan/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Uveal Neoplasms/*drug therapy/pathology
PMC - PMC7666275
OTO - NOTNLM
OT  - Chemosaturation
OT  - Cholangiocarcinoma
OT  - Hemihepatectomy
OT  - Melphalan
OT  - Metastatic uveal melanoma
OT  - Percutaneous locoregional therapy
COIS- The authors of this manuscript declare relationships with the following 
      companies: Siemens Healthcare and ProMedicus (Bernhard Meyer and Frank Wacker; 
      outside the submitted work). The remaining authors declare no relationships with 
      any companies whose products or services may be related to the subject matter of 
      the article. All authors declare no conflicts of interest.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/25 06:00
PMCR- 2020/10/09
CRDT- 2020/10/09 12:12
PHST- 2020/08/13 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/10/09 12:12 [entrez]
PHST- 2020/10/09 00:00 [pmc-release]
AID - 10.1007/s10585-020-10057-9 [pii]
AID - 10057 [pii]
AID - 10.1007/s10585-020-10057-9 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2020 Dec;37(6):683-692. doi: 10.1007/s10585-020-10057-9. 
      Epub 2020 Oct 9.